TY - JOUR
T1 - Retinal ganglion cell loss is associated with future disability worsening in early relapsing–remitting multiple sclerosis
AU - Wauschkuhn, Josephine
AU - Solorza Buenrostro, Gilberto
AU - Aly, Lilian
AU - Asseyer, Susanna
AU - Wicklein, Rebecca
AU - Hartberger, Julia Maria
AU - Ruprecht, Klemens
AU - Mühlau, Mark
AU - Schmitz-Hübsch, Tanja
AU - Chien, Claudia
AU - Berthele, Achim
AU - Brandt, Alexander U.
AU - Korn, Thomas
AU - Paul, Friedemann
AU - Hemmer, Bernhard
AU - Zimmermann, Hanna G.
AU - Knier, Benjamin
N1 - Publisher Copyright:
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
PY - 2023/4
Y1 - 2023/4
N2 - Background and purpose: Thinning of the retinal combined ganglion cell and inner plexiform layer (GCIP) as measured by optical coherence tomography (OCT) is a common finding in patients with multiple sclerosis. This study aimed to investigate whether a single retinal OCT analysis allows prediction of future disease activity after a first demyelinating event. Methods: This observational cohort study included 201 patients with recently diagnosed clinically isolated syndrome or relapsing–remitting multiple sclerosis from two German tertiary referral centers. Individuals underwent neurological examination, magnetic resonance imaging, and OCT at baseline and at yearly follow-up visits. Results: Patients were included at a median disease duration of 2.0 months. During a median follow-up of 59 (interquartile range = 43–71) months, 82% of patients had ongoing disease activity as demonstrated by failing the no evidence of disease activity 3 (NEDA-3) criteria, and 19% presented with confirmed disability worsening. A GCIP threshold of ≤77 μm at baseline identified patients with a high risk for NEDA-3 failure (hazard ratio [HR] = 1.7, 95% confidence interval [CI] = 1.1–2.8, p = 0.04), and GCIP measures of ≤69 μm predicted disability worsening (HR = 2.2, 95% CI = 1.2–4.3, p = 0.01). Higher rates of annualized GCIP loss increased the risk for disability worsening (HR = 2.5 per 1 μm/year increase of GCIP loss, p = 0.03). Conclusions: Ganglion cell thickness as measured by OCT after the initial manifestation of multiple sclerosis may allow early risk stratification as to future disease activity and progression.
AB - Background and purpose: Thinning of the retinal combined ganglion cell and inner plexiform layer (GCIP) as measured by optical coherence tomography (OCT) is a common finding in patients with multiple sclerosis. This study aimed to investigate whether a single retinal OCT analysis allows prediction of future disease activity after a first demyelinating event. Methods: This observational cohort study included 201 patients with recently diagnosed clinically isolated syndrome or relapsing–remitting multiple sclerosis from two German tertiary referral centers. Individuals underwent neurological examination, magnetic resonance imaging, and OCT at baseline and at yearly follow-up visits. Results: Patients were included at a median disease duration of 2.0 months. During a median follow-up of 59 (interquartile range = 43–71) months, 82% of patients had ongoing disease activity as demonstrated by failing the no evidence of disease activity 3 (NEDA-3) criteria, and 19% presented with confirmed disability worsening. A GCIP threshold of ≤77 μm at baseline identified patients with a high risk for NEDA-3 failure (hazard ratio [HR] = 1.7, 95% confidence interval [CI] = 1.1–2.8, p = 0.04), and GCIP measures of ≤69 μm predicted disability worsening (HR = 2.2, 95% CI = 1.2–4.3, p = 0.01). Higher rates of annualized GCIP loss increased the risk for disability worsening (HR = 2.5 per 1 μm/year increase of GCIP loss, p = 0.03). Conclusions: Ganglion cell thickness as measured by OCT after the initial manifestation of multiple sclerosis may allow early risk stratification as to future disease activity and progression.
KW - disability
KW - multiple sclerosis
KW - optical coherence tomography
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=85147358102&partnerID=8YFLogxK
U2 - 10.1111/ene.15681
DO - 10.1111/ene.15681
M3 - Article
C2 - 36635219
AN - SCOPUS:85147358102
SN - 1351-5101
VL - 30
SP - 982
EP - 990
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 4
ER -